ArticleDiabetes, obesity & metabolism2026
Glycaemic Control by Sociodemographic Factors in Adults With Type 1 Diabetes in England: Trends From 2007-2008 to 2023-2024.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycaemic Control by Sociodemographic Factors in Adults With Type 1 Diabetes in England: Trends From 2007-2008 to 2023-2024.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsThis study evaluated trends in glycaemic control in adults with Type 1 diabetes in England from 2007-2008 to 2023-2024, stratified by age, sex, ethnicity and socioeconomic deprivation. MATERIALS AND
methodsAdults aged ≥ 20 years from the National Diabetes Audit were analysed. Trends in mean HbA1c were assessed using linear mixed-effects models. Logistic regression examined associations between sociodemographic factors and having an HbA1c ≤ 58 mmol/mol (≤ 7.5%); odds ratios were converted to relative risks.
resultsIn 2007-2008, 32.6% of 133 035 adults had an HbA1c ≤ 58 mmol/mol, increasing to 39.1% of 226 005 adults in 2023-2024. Mean HbA1c declined from 68.8 (95% CI: 68.6-69.0) to 66.2 mmol/mol (95% CI: 66.1-66.3). By age, the largest improvement occurred in those aged 20-24 years, from 76.7 to 70.1 mmol/mol (p < 0.001), while adults > 64 years saw a non-significant increase from 63.7 to 63.8 mmol/mol (p = 0.203). Women consistently had higher mean HbA1c than men (2023-2024: 66.1 vs. 65.8 mmol/mol), declining from 69.4 to 66.1 mmol/mol in women and from 68.4 to 65.8 mmol/mol in men (both p < 0.001) and a lower adjusted probability of threshold attainment (38.4% [95% CI: 38.0-39.4] vs. 38.7% [95% CI: 38.2-39.3]). Marked ethnic inequalities persisted in 2023-2024: mean HbA1c was highest in Black (72.1 mmol/mol, 95% CI: 71.5-72.7) and Asian adults (69.8 mmol/mol, 95% CI: 69.4-70.2) compared with White adults (65.3 mmol/mol, 95% CI: 65.1-65.5). Socioeconomic gradients remained substantial, with threshold attainment at 46.4% (95% CI: 45.6-47.2) in the least deprived versus 32.3% (95% CI: 31.4-33.9) in the most deprived group.
conclusionsAlthough HbA1c improved overall, inequalities by age and deprivation widened, highlighting the need for equitable targeted care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.